APIMEDS PHARMACEUTICALS US, INC. Share-based Payment Arrangement, Expense
APIMEDS PHARMACEUTICALS US, INC. (APUS) reported Share-based Payment Arrangement, Expense of $105.21 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-14
- APIMEDS PHARMACEUTICALS US, INC. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $105.21K, a 45.22% decline year-over-year.
- APIMEDS PHARMACEUTICALS US, INC. share-based payment arrangement, expense for the quarter ending 2025-06-30 was $192.05K.
- APIMEDS PHARMACEUTICALS US, INC. share-based payment arrangement, expense for the quarter ending 2025-03-31 was $0.00.
- APIMEDS PHARMACEUTICALS US, INC. share-based payment arrangement, expense for the quarter ending 2024-03-31 was $0.00.
- APIMEDS PHARMACEUTICALS US, INC. share-based payment arrangement, expense for fiscal 2025 was $2.04M, a 2820.56% increase from fiscal 2024.
- APIMEDS PHARMACEUTICALS US, INC. share-based payment arrangement, expense for fiscal 2024 was $69.99K, a 0.00% change from fiscal 2023.
- APIMEDS PHARMACEUTICALS US, INC. share-based payment arrangement, expense for fiscal 2023 was $69.99K.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 3 month as first filed | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 6 month as first filed | Share-based Payment Arrangement, Expense 12 month | Share-based Payment Arrangement, Expense 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $105.21K 10-Q · filed 2026-08-14 | $219.38K 10-Q · filed 2026-08-14 | ||||
| 2025-12-31 | $2.04M 10-K · filed 2026-05-04 | |||||
| 2025-06-30 | $192.05K 10-Q · filed 2026-08-14 | $178.42K 10-Q · filed 2025-08-19 | $192.05K 10-Q · filed 2026-08-14 | $13.63K 10-Q · filed 2025-08-19 | ||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-20 | |||||
| 2024-12-31 | $69.99K 10-K · filed 2026-05-04 | $0.00 10-K · filed 2025-04-15 | ||||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-20 | |||||
| 2023-12-31 | $69.99K 10-K · filed 2025-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |